Literature DB >> 21041271

Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project).

Christopher Sjöwall1, Alf Kastbom, Gunnel Almroth, Jonas Wetterö, Thomas Skogh.   

Abstract

OBJECTIVE: To evaluate (1) to what extent sera from healthy subjects and patients with rheumatoid arthritis (RA) contain antibodies to bovine serum albumin (BSA); and (2) if anti-BSA antibodies interfere with results of enzyme-linked immunoassays (ELISA) containing BSA.
METHODS: The ELISA used was a previously developed in-house assay of autoantibodies to tumor necrosis factor (TNF). Anti-TNF and anti-BSA antibodies were analyzed by ELISA in 189 patients with early RA and 186 healthy blood donors. TNF preparations containing either BSA or human serum albumin (HSA) as carrier proteins were used as antigens in the anti-TNF assay. The presence and levels of antibodies were analyzed in relation to disease course and to the presence/absence of rheumatoid factor (RF).
RESULTS: In patients with RA, anti-TNF/BSA levels strongly correlated with anti-BSA levels (r = 0.81, p < 0.001), whereas anti-TNF/HSA did not (r = -0.09). Neither the presence nor the levels of anti-BSA in RA patients were associated with disease progression, and antibody levels were not significantly altered compared to controls (p = 0.11). IgG reactivity with TNF/HSA was neglible. In paired sera, preincubation with BSA abolished the anti-TNF/BSA reactivity. There were no indications of RF interference with anti-BSA or anti-TNF reactivity.
CONCLUSION: Antibodies to BSA are common in patients with RA as well as in healthy individuals. Their presence does not seem to be associated with RA disease activity or disease course, but may severely interfere with ELISA containing BSA. The use of BSA as a "blocking agent" or carrier protein in immunoassays should therefore be avoided.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041271     DOI: 10.3899/jrheum.100690

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

2.  Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Authors:  Helen Kaipe; Lena-Maria Carlson; Tom Erkers; Silvia Nava; Pia Molldén; Britt Gustafsson; Hua Qian; Xiaoguang Li; Takashi Hashimoto; Behnam Sadeghi; Mats Alheim; Olle Ringdén
Journal:  Stem Cells Dev       Date:  2015-03-13       Impact factor: 3.272

3.  Serology with ML Flow test in health professionals from three different states of Brazil.

Authors:  Karla Lucena Sampaio Calado; Mônica Maria Ferreira Magnanini; Rodrigo Scaliante de Moura; Maria Eugenia Noviski Gallo; Samira Bührer-Sékula; Maria Leide Wand-Del-Rey de Oliveira
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

4.  Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.

Authors:  Tadeja Kuret; Katja Lakota; Polonca Mali; Saša Čučnik; Sonja Praprotnik; Matija Tomšič; Snezna Sodin-Semrl
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.